FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038367086> ?p ?o ?g. }

• W2038367086 endingPage "583" @default.
• W2038367086 startingPage "575" @default.
• W2038367086 abstract "Fabry Disease (alpha-galactosidase A deficiency) is an X-linked hereditary disorder leading to the pathological accumulation of globotriaosylceramide (GL-3) in lysosomes, particularly in the vascular endothelium of the kidney, heart and brain. We report the results of an open-label phase 2 study that was undertaken to evaluate whether ethnic differences exist that would affect agalsidase beta (Fabrazyme) treatment of Fabry patients in the Japanese population, relative to safety and efficacy. The study design mirrored the design of the completed phase 3 clinical trial that led to approval of the product agalsidase beta. The 13 Japanese, male Fabry patients enrolled in the study received the enzyme replacement therapy over a period of 20 weeks as biweekly infusions. All selected efficacy end points showed improvements that were comparable with findings from the phase 3 study. These improvements included reductions of GL-3 accumulation in both kidney and skin capillary endothelial cells to (near) normal levels (92% of patients). Kidney and plasma GL-3 levels decreased by 51.9% and 100%, respectively, by ELISA. Renal function remained normal. Fabry-associated pain, and quality of life, showed improvement over baseline in multiple categories. Related adverse events were mild or moderate in intensity and mostly infusion-associated (fever and rigors). As expected, IgG antibody formation was observed in 85% of the patients, but had no effect on treatment response. These results suggest that treatment with agalsidase beta is safe and effective in Japanese patients with Fabry disease. With regard to safety and efficacy, no differences were observed as compared to the caucasian population." @default.
• W2038367086 created "2016-06-24" @default.
• W2038367086 creator A5004143066 @default.
• W2038367086 creator A5005035773 @default.
• W2038367086 creator A5010494013 @default.
• W2038367086 creator A5013740046 @default.
• W2038367086 creator A5015578380 @default.
• W2038367086 creator A5016675094 @default.
• W2038367086 creator A5019627435 @default.
• W2038367086 creator A5019881008 @default.
• W2038367086 creator A5021402208 @default.
• W2038367086 creator A5031388378 @default.
• W2038367086 creator A5033346305 @default.
• W2038367086 creator A5034883605 @default.
• W2038367086 creator A5053595622 @default.
• W2038367086 creator A5078779925 @default.
• W2038367086 creator A5078951101 @default.
• W2038367086 date "2003-06-07" @default.
• W2038367086 modified "2023-10-14" @default.
• W2038367086 title "Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study" @default.
• W2038367086 cites W1975365119 @default.
• W2038367086 cites W2022356406 @default.
• W2038367086 cites W2062214448 @default.
• W2038367086 cites W2073535884 @default.
• W2038367086 cites W2084201369 @default.
• W2038367086 cites W2091843493 @default.
• W2038367086 cites W2093722439 @default.
• W2038367086 cites W2304238562 @default.
• W2038367086 cites W2313827278 @default.
• W2038367086 cites W2328023011 @default.
• W2038367086 cites W2416949233 @default.
• W2038367086 cites W2010412782 @default.
• W2038367086 doi "https://doi.org/10.1007/s10545-005-0575-y" @default.
• W2038367086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15902561" @default.
• W2038367086 hasPublicationYear "2003" @default.
• W2038367086 type Work @default.
• W2038367086 sameAs 2038367086 @default.
• W2038367086 citedByCount "44" @default.
• W2038367086 countsByYear W20383670862012 @default.
• W2038367086 countsByYear W20383670862013 @default.
• W2038367086 countsByYear W20383670862014 @default.
• W2038367086 countsByYear W20383670862015 @default.
• W2038367086 countsByYear W20383670862016 @default.
• W2038367086 countsByYear W20383670862017 @default.
• W2038367086 countsByYear W20383670862018 @default.
• W2038367086 countsByYear W20383670862019 @default.
• W2038367086 countsByYear W20383670862020 @default.
• W2038367086 countsByYear W20383670862021 @default.
• W2038367086 countsByYear W20383670862022 @default.
• W2038367086 countsByYear W20383670862023 @default.
• W2038367086 crossrefType "journal-article" @default.
• W2038367086 hasAuthorship W2038367086A5004143066 @default.
• W2038367086 hasAuthorship W2038367086A5005035773 @default.
• W2038367086 hasAuthorship W2038367086A5010494013 @default.
• W2038367086 hasAuthorship W2038367086A5013740046 @default.
• W2038367086 hasAuthorship W2038367086A5015578380 @default.
• W2038367086 hasAuthorship W2038367086A5016675094 @default.
• W2038367086 hasAuthorship W2038367086A5019627435 @default.
• W2038367086 hasAuthorship W2038367086A5019881008 @default.
• W2038367086 hasAuthorship W2038367086A5021402208 @default.
• W2038367086 hasAuthorship W2038367086A5031388378 @default.
• W2038367086 hasAuthorship W2038367086A5033346305 @default.
• W2038367086 hasAuthorship W2038367086A5034883605 @default.
• W2038367086 hasAuthorship W2038367086A5053595622 @default.
• W2038367086 hasAuthorship W2038367086A5078779925 @default.
• W2038367086 hasAuthorship W2038367086A5078951101 @default.
• W2038367086 hasConcept C126322002 @default.
• W2038367086 hasConcept C141071460 @default.
• W2038367086 hasConcept C159641895 @default.
• W2038367086 hasConcept C197934379 @default.
• W2038367086 hasConcept C2776788019 @default.
• W2038367086 hasConcept C2777404818 @default.
• W2038367086 hasConcept C2777687718 @default.
• W2038367086 hasConcept C2779134260 @default.
• W2038367086 hasConcept C2779969927 @default.
• W2038367086 hasConcept C2780091579 @default.
• W2038367086 hasConcept C71924100 @default.
• W2038367086 hasConcept C90924648 @default.
• W2038367086 hasConceptScore W2038367086C126322002 @default.
• W2038367086 hasConceptScore W2038367086C141071460 @default.
• W2038367086 hasConceptScore W2038367086C159641895 @default.
• W2038367086 hasConceptScore W2038367086C197934379 @default.
• W2038367086 hasConceptScore W2038367086C2776788019 @default.
• W2038367086 hasConceptScore W2038367086C2777404818 @default.
• W2038367086 hasConceptScore W2038367086C2777687718 @default.
• W2038367086 hasConceptScore W2038367086C2779134260 @default.
• W2038367086 hasConceptScore W2038367086C2779969927 @default.
• W2038367086 hasConceptScore W2038367086C2780091579 @default.
• W2038367086 hasConceptScore W2038367086C71924100 @default.
• W2038367086 hasConceptScore W2038367086C90924648 @default.
• W2038367086 hasIssue "4" @default.
• W2038367086 hasLocation W20383670861 @default.
• W2038367086 hasLocation W20383670862 @default.
• W2038367086 hasOpenAccess W2038367086 @default.
• W2038367086 hasPrimaryLocation W20383670861 @default.
• W2038367086 hasRelatedWork W186628991 @default.
• W2038367086 hasRelatedWork W2012825594 @default.
• W2038367086 hasRelatedWork W2025323739 @default.

• next